Menu
Back to Journals » Substance Abuse and Rehabilitation » Volume 11
An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]
Authors Ling W , Farabee D , Nadipelli VR , Perrochet B
Received 21 November 2019
Accepted for publication 6 February 2020
Published 17 February 2020 Volume 2020:11 Pages 21—22
DOI https://doi.org/10.2147/SAR.S239507
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Stephan Arndt
Walter Ling,1 David Farabee,2,3 Vijay R Nadipelli,4 Brian Perrochet3 On behalf of the TEA Development Group
1Department of Family Medicine, Center for Behavioral and Addiction Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 2Department of Population Health, New York University School of Medicine, New York, NY, USA; 3Department of Psychiatry and Biobehavioral Sciences Semel Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 4Global Health Economics and Outcome Research, Indivior Inc., Richmond, VA, USA
Correspondence: Walter Ling Tel +1 310 993 8111
Email [email protected]
The authors are pleased to provide this updated version of the TEA to the community of clinicians and researchers using the TEA. Previous to its original publication in 2012,1 the TEA had been used for five years by clinicians in office-based and hospital-based treatment settings, as well as by researchers in pilot projects. The TEA’s utility and psychometrics were recently studied in a large clinical trial of extended-release buprenorphine for opioid use disorder, demonstrating moderate to strong reliability and validity.3 The TEA has been widely adopted by researchers and clinicians in the United States and around the world. It has been translated into Spanish, Chinese, Lithuanian, and Arabic, and is being used in Europe, Asia, the Americas, and the Middle-East.
View the original paper by Ling and colleagues
Dear editor
The authors are pleased to provide this updated version of the TEA to the community of clinicians and researchers using the TEA. Previous to its original publication in 2012,1 the TEA had been used for five years by clinicians in office-based and hospital-based treatment settings, as well as by researchers in pilot projects. The TEA’s utility and psychometrics were recently studied in a large clinical trial of extended-release buprenorphine for opioid use disorder, demonstrating moderate to strong reliability and validity.3 The TEA has been widely adopted by researchers and clinicians in the United States and around the world. It has been translated into Spanish, Chinese, Lithuanian, and Arabic, and is being used in Europe, Asia, the Americas, and the Middle-East.
Shortly after the 2012 publication we received many queries about the TEA, some of which were addressed in a Letter to the Editor published in 2013.2 One frequent question has to do with its use at “baseline” and its subsequent use as a status report. To address that issue more definitively, we are presenting this updated TEA (see Supplementary Materials), which has been slightly rephrased to make it more suitable for use at baseline while remaining wholly suitable for subsequent use to measure the patient’s progress during treatment and recovery.
We encourage all users of the TEA to stay in touch with us by requesting permission for its use to [email protected] so that we can continue to update you on the future development of the TEA.
Note to Users of the TEA (Clinicians and Researchers)
Because the TEA appears so simple and straightforward, it is tempting to simply hand it to patients to be self-administered. We want to emphasize the importance of spending a few minutes to explain to patients that the TEA, although brief, is a comprehensive assessment of their life status, obtained from their perspectives. The apparent simplicity is a function of the instrument’s recognition of the patient’s powerful capacity to quickly assess the state of his/her life situations as they are meaningful to the patient relative to the domains of the TEA. We also want to emphasize the importance of encouraging patients to provide remarks that elucidate their specific life experiences that led them to provide the scores they marked.
Disclosure
Dr Walter Ling reports personal fees from Indivior Pharmaceuticals, outside the submitted work. The authors report no other conflicts of interest in this communication.
References
1. Ling W, Farabee D, Liepa D, Wu LT. The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. Subst Abuse Rehabil. 2012;3:129–136. doi:10.2147/SAR.S38902
2. Ling W, Farabee D, Liepa D, Wu LT. Letter to the editor: the Treatment Effectiveness Assessment (TEA). Subst Abuse Rehabil. 2013;4:73–74. doi:10.2147/SAR.S48737
3. Ling W, Nadipelli V, Solem C, et al. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019;10:13–21. doi:10.2147/SAR.S198361
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.